Bank of America
SGMO

Bank of America’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bank of America’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$452K Buy
1,838,390
+1,744,406
+1,856% +$694K ﹤0.01% 4946
2025
Q4 		$39.5K Sell
93,984
-6,486
-6% -$3.44K ﹤0.01% 5904
2025
Q3 		$67.6K Sell
100,470
-7,500
-7% -$4.04K ﹤0.01% 6749
2025
Q2 		$58.4K Sell
107,970
-12,807
-11% -$7.61K ﹤0.01% 6757
2025
Q1 		$79.1K Sell
120,777
-210,479
-64% -$223K ﹤0.01% 6589
2024
Q4 		$338K Buy
331,256
+212,638
+179% +$389K ﹤0.01% 5817
2024
Q3 		$103K Sell
118,618
-39,613
-25% -$29K ﹤0.01% 6313
2024
Q2 		$56.6K Sell
158,231
-110,829
-41% -$59.9K ﹤0.01% 6477
2024
Q1 		$180K Buy
269,060
+38,266
+17% +$27.8K ﹤0.01% 5934
2023
Q4 		$125K Sell
230,794
-1,004,404
-81% -$463K ﹤0.01% 6289
2023
Q3 		$740K Buy
1,235,198
+841,460
+214% +$901K ﹤0.01% 5029
2023
Q2 		$512K Sell
393,738
-773,993
-66% -$1.06M ﹤0.01% 5269
2023
Q1 		$2.06M Buy
1,167,731
+54,041
+5% +$154K ﹤0.01% 4330
2022
Q4 		$3.5M Buy
1,113,690
+346,345
+45% +$1.34M ﹤0.01% 3747
2022
Q3 		$3.76M Buy
767,345
+68,276
+10% +$351K ﹤0.01% 3639
2022
Q2 		$2.89M Sell
699,069
-44,664
-6% -$193K ﹤0.01% 3955
2022
Q1 		$4.32M Buy
743,733
+315,942
+74% +$1.88M ﹤0.01% 3784
2021
Q4 		$3.21M Sell
427,791
-29,669
-6% -$258K ﹤0.01% 4091
2021
Q3 		$4.12M Buy
457,460
+99,374
+28% +$982K ﹤0.01% 3753
2021
Q2 		$4.29M Buy
358,086
+2,223
+0.6% +$25.2K ﹤0.01% 3660
2021
Q1 		$4.46M Buy
355,863
+102,693
+41% +$1.38M ﹤0.01% 3515
2020
Q4 		$3.95M Sell
253,170
-33,024
-12% -$387K ﹤0.01% 3346
2020
Q3 		$2.7M Buy
286,194
+43,023
+18% +$465K ﹤0.01% 3444
2020
Q2 		$2.18M Buy
243,171
+153,597
+171% +$1.42M ﹤0.01% 3554
2020
Q1 		$571K Sell
89,574
-20,305
-18% -$151K ﹤0.01% 4418
2019
Q4 		$920K Sell
109,879
-141,482
-56% -$1.3M ﹤0.01% 4568
2019
Q3 		$2.27M Sell
251,361
-44,495
-15% -$499K ﹤0.01% 3939
2019
Q2 		$3.19M Sell
295,856
-194,970
-40% -$2.07M ﹤0.01% 3639
2019
Q1 		$4.68M Buy
490,826
+331,014
+207% +$3.38M ﹤0.01% 3228
2018
Q4 		$1.83M Buy
159,812
+46,981
+42% +$584K ﹤0.01% 3921
2018
Q3 		$1.91M Sell
112,831
-101,589
-47% -$1.54M ﹤0.01% 4013
2018
Q2 		$3.04M Buy
214,420
+127,191
+146% +$2.11M ﹤0.01% 3631
2018
Q1 		$1.66M Buy
87,229
+62,643
+255% +$1.34M ﹤0.01% 4020
2017
Q4 		$403K Sell
24,586
-2,286
-9% -$34K ﹤0.01% 5079
2017
Q3 		$403K Buy
26,872
+9,295
+53% +$103K ﹤0.01% 5075
2017
Q2 		$154K Sell
17,577
-15,048
-46% -$96.5K ﹤0.01% 5425
2017
Q1 		$169K Buy
32,625
+10,861
+50% +$43.6K ﹤0.01% 5390
2016
Q4 		$66K Sell
21,764
-466
-2% -$1.7K ﹤0.01% 5807
2016
Q3 		$103K Sell
22,230
-6,927
-24% -$35.2K ﹤0.01% 5431
2016
Q2 		$169K Buy
29,157
+12,261
+73% +$78.1K ﹤0.01% 5289
2016
Q1 		$102K Sell
16,896
-73,120
-81% -$439K ﹤0.01% 5477
2015
Q4 		$822K Sell
90,016
-6,669
-7% -$51.4K ﹤0.01% 4483
2015
Q3 		$546K Sell
96,685
-54,223
-36% -$447K ﹤0.01% 4749
2015
Q2 		$1.67M Buy
150,908
+50,214
+50% +$647K ﹤0.01% 3639
2015
Q1 		$1.58M Sell
100,694
-10,845
-10% -$168K ﹤0.01% 3440
2014
Q4 		$1.7M Sell
111,539
-20,803
-16% -$253K ﹤0.01% 3548
2014
Q3 		$1.43M Sell
132,342
-39,216
-23% -$512K ﹤0.01% 3680
2014
Q2 		$2.62M Sell
171,558
-194,390
-53% -$2.8M ﹤0.01% 3127
2014
Q1 		$6.62M Buy
365,948
+44,474
+14% +$857K ﹤0.01% 2152
2013
Q4 		$4.47M Buy
321,474
+30,287
+10% +$349K ﹤0.01% 2574
2013
Q3 		$3.06M Sell
291,187
-63,339
-18% -$629K ﹤0.01% 2839
2013
Q2 		$2.77M Buy
+354,526
New +$3.09M ﹤0.01% 2855

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Bank of America's SGMO Position: Q1 2026 in Review

Bank of America increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 1,856% in Q1 2026, buying an estimated $694K and bringing the position to 1,838,390 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #4946.

Bank of America first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.62M in Q1 2014. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Bank of America held 1,838,390 shares of SANGAMO THERAPEUTICS INC worth $452K as of Q1 2026.
  • Bank of America bought 1,744,406 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $694K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4946 holding.
  • Bank of America first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's SANGAMO THERAPEUTICS INC position peaked at $6.62M in Q1 2014.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.